Lecture

Protein Aggregation and Disaggregation: Insights from In Vivo Studies

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Description

This lecture by Helen Saibil delves into the mechanisms of protein aggregation and disaggregation in vivo and in vitro, focusing on the case of huntingtin protein in Huntington's Disease. The presentation covers the formation of different types of aggregates, the role of polyQ repeats in toxicity, and the impact of aggregation on disease progression. Saibil also discusses the importance of cytoplasmic aggregates in disease severity, the heterogeneity of mutant huntingtin aggregates, and the machinery involved in reversing aggregation. Through various microscopy techniques, the lecture reveals the unexpected cellular pathways of huntingtin aggregation and the machinery responsible for disassembling amyloid fibrils.

Official source

Related concepts (32)

Amyloid

Amyloids are aggregates of proteins characterised by a fibrillar morphology of typically 7–13 nm in diameter, a β-sheet secondary structure (known as cross-β) and ability to be stained by particular dyes, such as Congo red. In the human body, amyloids have been linked to the development of various diseases. Pathogenic amyloids form when previously healthy proteins lose their normal structure and physiological functions (misfolding) and form fibrous deposits within and around cells.

Amyloid beta

Amyloid beta (Aβ or Abeta) denotes peptides of 36–43 amino acids that are the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid-beta precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ in a cholesterol-dependent process and substrate presentation. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms.

Protein aggregation

In molecular biology, protein aggregation is a phenomenon in which intrinsically-disordered or mis-folded proteins aggregate (i.e., accumulate and clump together) either intra- or extracellularly. Protein aggregates have been implicated in a wide variety of diseases known as amyloidoses, including ALS, Alzheimer's, Parkinson's and prion disease. After synthesis, proteins typically fold into a particular three-dimensional conformation that is the most thermodynamically favorable: their native state.

Huntington's disease

Huntington's disease (HD), also known as Huntington's chorea, is an incurable neurodegenerative disease that is mostly inherited. The earliest symptoms are often subtle problems with mood or mental/ psychiatric abilities. A general lack of coordination and an unsteady gait often follow. It is also a basal ganglia disease causing a hyperkinetic movement disorder known as chorea. As the disease advances, uncoordinated, involuntary body movements of chorea become more apparent.

Amyloidosis

Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several non-specific and vague signs and symptoms associated with amyloidosis. These include fatigue, peripheral edema, weight loss, shortness of breath, palpitations, and feeling faint with standing. In AL amyloidosis, specific indicators can include enlargement of the tongue and periorbital purpura.

Related lectures (64)

Protein Aggregation in Neurodegenerative Diseases

Explores protein aggregation in neurodegenerative diseases, emphasizing the need to rethink treatment strategies and understand the role of post-translational modifications.

Chaperone-Mediated Disaggregation: Amyloid Fibrils and Hsp70

Explores chaperone-mediated disaggregation of amyloid fibrils by Hsp70 in neurodegenerative diseases.

Protein Aggregation Control

Explores protein aggregation control through optimal strategies, inhibitors, and spatial regulation using liquid compartments, shedding light on drug interventions and aggregate dynamics.

Polyglutamine Protein Aggregation: Molecular Structure and Pathogenic Mechanisms

Explores beta-hairpins in polyglutamine protein aggregation, focusing on Huntington's disease and the molecular mechanisms behind toxic fibril formation.

Molecular Chaperone Action: Small Heat Shock Proteins